Alnylam Pharmaceuticals Inc. (ALNY)’s Financial Results Comparing With Translate Bio Inc. (NASDAQ:TBIO)

Both Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Translate Bio Inc. (NASDAQ:TBIO) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alnylam Pharmaceuticals Inc. 79 92.05 N/A -7.88 0.00
Translate Bio Inc. 10 132.67 N/A -2.44 0.00

Demonstrates Alnylam Pharmaceuticals Inc. and Translate Bio Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 shows us the net margins, return on assets and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals Inc. 0.00% -53.9% -45.5%
Translate Bio Inc. 0.00% 0% 0%

Liquidity

The Current Ratio and a Quick Ratio of Alnylam Pharmaceuticals Inc. are 9.3 and 9.1. Competitively, Translate Bio Inc. has 7.7 and 7.7 for Current and Quick Ratio. Alnylam Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Translate Bio Inc.

Analyst Ratings

The Ratings and Recommendations for Alnylam Pharmaceuticals Inc. and Translate Bio Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alnylam Pharmaceuticals Inc. 0 2 6 2.75
Translate Bio Inc. 0 0 1 3.00

Alnylam Pharmaceuticals Inc. has a 40.87% upside potential and a consensus price target of $117.89. Competitively Translate Bio Inc. has a consensus price target of $21, with potential upside of 98.49%. The data from earlier shows that analysts opinion suggest that Translate Bio Inc. seems more appealing than Alnylam Pharmaceuticals Inc.

Institutional & Insider Ownership

Alnylam Pharmaceuticals Inc. and Translate Bio Inc. has shares held by institutional investors as follows: 89.2% and 58.3%. Insiders held roughly 0.5% of Alnylam Pharmaceuticals Inc.’s shares. On the other hand, insiders held about 31.15% of Translate Bio Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alnylam Pharmaceuticals Inc. 1.45% 7.75% -6.55% -5.03% -19.85% 6.42%
Translate Bio Inc. -9.89% -33.66% -14.41% 41.7% -34.32% 6.93%

For the past year Alnylam Pharmaceuticals Inc.’s stock price has smaller growth than Translate Bio Inc.

Summary

Translate Bio Inc. beats on 7 of the 9 factors Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.